Last Updated: August 9, 2026

JAVADIN Drug Patent Profile

Name: JAVADIN Drug Patent, Exclusivity, and Generic Launch Dataset
Creator: DrugPatentWatch
License: https://www.drugpatentwatch.com/terms.php

✉ Email this page to a colleague

« Back to Dashboard

Which patents cover Javadin, and when can generic versions of Javadin launch?

Javadin is a drug marketed by Azurity and is included in one NDA. There are two patents protecting this drug.

The generic ingredient in JAVADIN is clonidine hydrochloride. There are twenty-two drug master file entries for this compound. Forty-three suppliers are listed for this compound. Additional details are available on the clonidine hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Javadin

A generic version of JAVADIN was approved as clonidine hydrochloride by ACTAVIS ELIZABETH on December 16^th, 1986.

Start Trial

AI Deep Research

Questions you can ask:

What is the 5 year forecast for JAVADIN?
What are the global sales for JAVADIN?
What is Average Wholesale Price for JAVADIN?

Summary for JAVADIN

US Patents:	2
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Drug Prices:	Drug price information for JAVADIN
What excipients (inactive ingredients) are in JAVADIN?	JAVADIN excipients list
DailyMed Link:	JAVADIN at DailyMed

Drug patent expirations by year for JAVADIN

Pharmacology for JAVADIN

Drug Class	Central alpha-2 Adrenergic Agonist
Mechanism of Action	Adrenergic alpha2-Agonists

US Patents and Regulatory Information for JAVADIN

JAVADIN is protected by two US patents.

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Azurity	JAVADIN	clonidine hydrochloride	SOLUTION;ORAL	220256-001	Oct 23, 2025		RX	Yes	Yes	12,233,049	⤷ Start Trial	Y			⤷ Start Trial
Azurity	JAVADIN	clonidine hydrochloride	SOLUTION;ORAL	220256-001	Oct 23, 2025		RX	Yes	Yes	12,440,474	⤷ Start Trial	Y			⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.